Duyuru • May 22
Haoxi Health Technology Limited, Annual General Meeting, Jun 02, 2026 Haoxi Health Technology Limited, Annual General Meeting, Jun 02, 2026, at 09:30 China Standard Time. Location: at room 801, tower c, floor 8, building 103, huizhongli, chaoyang district, beijing China Duyuru • May 20
Haoxi Health Technology Limited announced that it expects to receive $0.72 million in funding Haoxi Health Technology Limited announced that it has entered into a Securities Purchase Agreement with Zhen Fan the Company’s Chief Executive Officer and the chairman of the board of the directors pursuant to which the Company agreed to issue and sell to the Purchaser, and the Purchaser agreed to purchase from the Company, 40,000,000 Class B ordinary shares at a par value of $0.0025 per share at an issue price of $0.018 per share for gross proceeds of 720,000 on May 18, 2026. The transaction is subject to the terms and conditions set forth in the Purchase Agreement. The purchase price per Share represents approximately 101.12% of the closing price of the Company’s Class A ordinary shares as reported on Nasdaq.com on May 18, 2026. The issue price per Share represents approximately 101.12% of the closing price of the Company’s Class A ordinary shares as reported on Nasdaq.com on May 18, 2026. The Purchase Agreement contains customary representations, warranties, covenants, closing conditions and indemnification provisions of the Company and the Purchaser. The closing of the transaction is subject to the satisfaction or waiver of customary closing conditions set forth in the Purchase Agreement, including, among others, the delivery of the purchase price by the Purchaser and the issuance of the Shares by the Company. The transaction contemplated by the Purchase Agreement constitutes a related-party transaction. The transaction is approved by audit committee of the Board. The transaction contemplated by the Purchase Agreement is expected to close on or about May 19, 2026.Immediately following the closing of the transaction contemplated by the Purchase Agreement, the Purchaser will beneficially own 40,690,800 Class B ordinary shares, representing approximately 83.83% of the aggregate voting power of the Company’s outstanding ordinary shares. Duyuru • May 14
Haoxi Health Technology Limited has completed a Follow-on Equity Offering in the amount of $6.4558 million. Haoxi Health Technology Limited has completed a Follow-on Equity Offering in the amount of $6.4558 million.
Security Name: Class A Ordinary Shares
Security Type: Common Stock
Securities Offered: 9,000,000
Price\Range: $0.25
Discount Per Security: $0.0175
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant
Securities Offered: 16,999,998
Price\Range: $0.2474
Discount Per Security: $0.0173
Transaction Features: Registered Direct Offering Duyuru • May 12
Haoxi Health Technology Limited has filed a Follow-on Equity Offering in the amount of $4.2725 million. Haoxi Health Technology Limited has filed a Follow-on Equity Offering in the amount of $4.2725 million.
Security Name: Class A Ordinary Shares
Security Type: Common Stock
Securities Offered: 9,000,000
Price\Range: $0.0025
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant
Securities Offered: 16,999,998
Price\Range: $0.25
Transaction Features: Registered Direct Offering Reported Earnings • Apr 27
First half 2026 earnings released: US$1.53 loss per share (vs US$3.20 loss in 1H 2025) First half 2026 results: US$1.53 loss per share. Revenue: US$33.8m (up 41% from 1H 2025). Net loss: US$6.88m (loss widened US$6.65m from 1H 2025). Valuation Update With 7 Day Price Move • Mar 30
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to US$1.05, the stock trades at a trailing P/E ratio of 16.1x. Average trailing P/E is 14x in the Media industry in the US. Total loss to shareholders of 17% over the past year. Valuation Update With 7 Day Price Move • Feb 27
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to US$1.29, the stock trades at a trailing P/E ratio of 19.7x. Average trailing P/E is 24x in the Media industry in the US. Total loss to shareholders of 29% over the past year. Valuation Update With 7 Day Price Move • Feb 06
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to US$1.10, the stock trades at a trailing P/E ratio of 16.9x. Average trailing P/E is 15x in the Media industry in the US. Total loss to shareholders of 42% over the past year. Duyuru • Jan 24
Haoxi Health Technology Limited has filed a Follow-on Equity Offering in the amount of $80 million. Haoxi Health Technology Limited has filed a Follow-on Equity Offering in the amount of $80 million.
Security Name: Class A Ordinary Shares
Security Type: Common Stock
Transaction Features: At the Market Offering New Risk • Jan 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (113% accrual ratio). Shareholders have been substantially diluted in the past year (190% increase in shares outstanding). Market cap is less than US$10m (US$9.50m market cap). Minor Risk Share price has been volatile over the past 3 months (9.2% average weekly change). Valuation Update With 7 Day Price Move • Jan 09
Investor sentiment improves as stock rises 40% After last week's 40% share price gain to US$1.46, the stock trades at a trailing P/E ratio of 3.1x. Average trailing P/E is 14x in the Media industry in the US. Total loss to shareholders of 62% over the past year. Duyuru • Dec 04
Haoxi Health Technology Limited announced that it has received $5 million in funding On December 3, 2025, Haoxi Health Technology Limited closed the transaction. Valuation Update With 7 Day Price Move • Nov 28
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to US$1.07, the stock trades at a trailing P/E ratio of 2.3x. Average trailing P/E is 15x in the Media industry in the US. Total loss to shareholders of 67% over the past year. Reported Earnings • Oct 21
Full year 2025 earnings released: EPS: US$1.66 (vs US$1.06 in FY 2024) Full year 2025 results: EPS: US$1.66 (up from US$1.06 in FY 2024). Revenue: US$32.8m (down 32% from FY 2024). Net income: US$3.88m (up 200% from FY 2024). Profit margin: 12% (up from 2.7% in FY 2024). The increase in margin was driven by lower expenses. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to US$1.09, the stock trades at a trailing P/E ratio of 10.3x. Average trailing P/E is 20x in the Media industry in the US. Total loss to shareholders of 78% over the past year. Valuation Update With 7 Day Price Move • Sep 10
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to US$1.37, the stock trades at a trailing P/E ratio of 12.9x. Average trailing P/E is 21x in the Media industry in the US. Total loss to shareholders of 99% over the past year. Valuation Update With 7 Day Price Move • May 26
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to US$1.59, the stock trades at a trailing P/E ratio of 15x. Average trailing P/E is 18x in the Media industry in the US. Total loss to shareholders of 99% over the past year. Valuation Update With 7 Day Price Move • May 06
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to US$1.39, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 15x in the Media industry in the US. Total loss to shareholders of 99% over the past year. Reported Earnings • Apr 28
First half 2025 earnings released: US$0.13 loss per share (vs US$0.65 profit in 1H 2024) First half 2025 results: US$0.13 loss per share (down from US$0.65 profit in 1H 2024). Revenue: US$24.0m (up 1.9% from 1H 2024). Net loss: US$232.5k (down 131% from profit in 1H 2024). New Risk • Apr 27
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.6% Last year net profit margin: 3.0% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). High level of non-cash earnings (95% accrual ratio). Shareholders have been substantially diluted in the past year (119% increase in shares outstanding). Market cap is less than US$10m (US$3.98m market cap). Minor Risk Profit margins are more than 30% lower than last year (0.6% net profit margin). Duyuru • Apr 15
Haoxi Health Technology Limited Announces CFO Changes On April 10, 2025, Ms. Yu Guo notified Haoxi Health Technology Limited of her resignation as Chief Financial Officer (“CFO”) of the Company, effective as of April 10, 2025. Ms. Yu Guo has advised the Company that her resignation was due to personal reasons and not a result of any disagreement with the Company on any matter related to the operations, policies, or practices of the Company. To fill the vacancy created by Ms. Yu Guo’s departure, on April 11, 2025, the Board of Directors the Company appointed Ms. Dongxue Li as CFO, effective on April 12, 2025. The appointment of Ms. Li as CFO has a term of one year and may be extended for successive one-year terms, subject to earlier resignation or removal. She will receive an annual compensation of $12,000. The biographical information of Ms. Li is set forth below. Since August 2024, Ms. Dongxue Li has acted as the financial reporting manager at Beijing Haoxi Digital Technology Co. Ltd., a wholly owned operating subsidiary of the Company. Prior to joining the Company, Ms. Li worked at the Shanghai Youtuo Public Relations Consulting Co. Ltd. from 2012 to 2022, and she served as the senior finance manager of this company from July 2020 to December 2022, in charge of the financial reporting and internal control matters. Ms. Li earned her Bachelor’s degree in Accounting from the Northern College of Beijing University of Chemical Technology in 2011. She obtained the junior accounting professional qualification in China. Valuation Update With 7 Day Price Move • Apr 11
Investor sentiment improves as stock rises 31% After last week's 31% share price gain to US$1.28, the stock trades at a trailing P/E ratio of 2.8x. Average trailing P/E is 14x in the Media industry in the US. Total loss to shareholders of 99% over the past year. Valuation Update With 7 Day Price Move • Mar 20
Investor sentiment improves as stock rises 26% After last week's 26% share price gain to US$1.97, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 13x in the Media industry in the US. Total loss to shareholders of 99% over the past year. Valuation Update With 7 Day Price Move • Mar 03
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to US$1.71, the stock trades at a trailing P/E ratio of 3.7x. Average trailing P/E is 15x in the Media industry in the US. Total loss to shareholders of 99% over the past year. Duyuru • Feb 12
Haoxi Health Technology Regains Compliance with Nasdaq Minimum Closing Bid Price Rule Haoxi Health Technology Limited announced that it received a formal notification from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company’s Class A ordinary shares, par value $0.0025 each (the “Ordinary Shares”) to maintain a minimum bid price of $1.00 per share. The Nasdaq staff made this determination of compliance after the closing bid price of the Company’s Ordinary Shares has been at $1.00 per share or greater for the last 10 consecutive business days from January 27, 2025, to February 7, 2025. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and this bid price deficiency matter is now closed. New Risk • Jan 28
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 121% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). High level of non-cash earnings (59% accrual ratio). Shareholders have been substantially diluted in the past year (121% increase in shares outstanding). Market cap is less than US$10m (US$7.29m market cap). Valuation Update With 7 Day Price Move • Jan 27
Investor sentiment deteriorates as stock falls 26% After last week's 26% share price decline to US$2.58, the stock trades at a trailing P/E ratio of 38.8x. Average trailing P/E is 14x in the Media industry in the US. Total loss to shareholders of 98% over the past year. Duyuru • Dec 20
Haoxi Health Technology Limited, Annual General Meeting, Jan 10, 2025 Haoxi Health Technology Limited, Annual General Meeting, Jan 10, 2025, at 10:00 China Standard Time. Location: room 801, tower c, floor 8, building 103, huizhongli, chaoyang district, beijing China Reported Earnings • Oct 30
Full year 2024 earnings released: EPS: US$0.04 (vs US$0.035 in FY 2023) Full year 2024 results: EPS: US$0.04 (up from US$0.035 in FY 2023). Revenue: US$48.5m (up 72% from FY 2023). Net income: US$1.29m (up 33% from FY 2023). Profit margin: 2.7% (down from 3.4% in FY 2023). The decrease in margin was driven by higher expenses. Duyuru • Oct 07
Haoxi Health Technology Limited Provides Preliminary Unaudited Earnings Guidance for the Fiscal Year Ended June 30, 2024 Haoxi Health Technology Limited provided preliminary unaudited earnings guidance for the fiscal year ended June 30, 2024. For the year, the company expects revenue to be approximately $48.52 million, reflecting a 72% increase compared to $28.23 million in the fiscal year ended June 30, 2023 (FY23). Net Income to be approximately $1.29 million, reflecting a 33.2% increase from $0.97 million in FY23. Duyuru • Sep 20
Haoxi Health Technology Limited has completed a Composite Units Offering in the amount of $12 million. Haoxi Health Technology Limited has completed a Composite Units Offering in the amount of $12 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 4,000,000
Price\Range: $3
Discount Per Security: $0.21 New Risk • Sep 18
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$91.2m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (24% average weekly change). Minor Risk Market cap is less than US$100m (US$91.2m market cap). Valuation Update With 7 Day Price Move • Sep 17
Investor sentiment deteriorates as stock falls 29% After last week's 29% share price decline to US$2.83, the stock trades at a trailing P/E ratio of 71.1x. Average trailing P/E is 14x in the Media industry in the US. Valuation Update With 7 Day Price Move • Aug 15
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to US$3.07, the stock trades at a trailing P/E ratio of 77.2x. Average trailing P/E is 12x in the Media industry in the US. New Risk • Aug 13
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$89.6m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (23% average weekly change). Minor Risk Market cap is less than US$100m (US$89.6m market cap). Board Change • Feb 01
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. CEO & Chairman of the Board of Directors Zhen Fan is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.